Navigation Links
Nile Therapeutics Completes Dosing of Phase II Study
Date:7/7/2010

patient visit to occur at the end of July. Final results from the study are expected in the fourth quarter of 2010.

"We are extremely pleased to announce the completion of enrollment for this study and look forward to being able to discuss our data later this year," said Joshua A. Kazam, Nile's CEO. "We believe that CD-NP has the potential to be an exciting new therapy that provides unique clinical benefit to patients with cardiovascular and renal disease.  Our next steps in the development of CD-NP as therapy for acute heart failure are to finalize the design of a double-blind, placebo controlled Phase IIb study and to discuss that trial design with the FDA and other regulatory authorities.  We look forward to those discussions and to the continued advancement of the CD-NP program."

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel, rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a second novel, rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of his
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... issued the following open letter to shareholders from ... Med. Sc. Dear RXi Shareholders, ... of inaccurate statements posted on certain social media ...
(Date:12/22/2014)... Dec. 22, 2014  Pfenex Inc. (NYSE MKT: PFNX) ... vaccine, has been filed and is now open and ... the Department of Health and Human Services (HHS), through ... "We are extremely pleased to have the IND ... represents a significant milestone in our company,s partnership with ...
(Date:12/19/2014)... -- In the Friday, December 19 edition of USA ... Technology (HIT) features Konica Minolta, the company announced today. The supplement ... leading healthcare organizations. In addition to the print ... as New York , Chicago ... Minneapolis and San Francisco ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2
... Ambrx Inc. today announced that Ho Cho, Ph.D., ... from the company,s antibody drug conjugate (ADC) programs at ... obtained from recent xenograft studies comparing Ambrx ADCs with ... technology has been clinically validated as safe and efficacious ...
... 22, 2011 Naurex Inc., a clinical-stage ... psychiatry and neurology, today announced that it has initiated ... GLYX-13.  GLYX-13, a Glycine-site Functional Partial Agonist (GFPA) selective ... developed as a therapy for patients who are not ...
Cached Medicine Technology:Ambrx to Present Data from Antibody Drug Conjugate Program at Upcoming Scientific Conferences 2Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression 2Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression 3
(Date:12/22/2014)... International efforts to combat ... are receiving further support from recent initiatives ... (NGOs) and other charitable organizations. While research ... responders, patients and others can immediately benefit ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... -- A new vaccine created to fight an illness ... protect livestock and even humans from similar brain infections, ... deer from becoming infected by the incurable brain disorder ... in the Dec. 21 online edition of the journal ... mysterious infectious particles known as prions that go rogue. ...
(Date:12/22/2014)... 22, 2014 The Bob Woodruff ... having invested more than $5 million in programs ... and their families. , This includes $1.3 million ... nonprofits, helping with: veteran entrepreneurship; community impact; vocational ... for severely injured veterans. , “The needs of ...
(Date:12/22/2014)... 22, 2014 Explorys, the leader in ... its leadership team: Greg Yarrington as Vice President of ... Patrick Wells as Vice President of Solutions. These new ... new jobs in 2015 to support client demand for ... platform-as-a-service offerings, and growth of its partner network. ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Give a ... season, the gift of health and vitality. , For ... its three top-selling anti-aging formulas in special Holiday Wellness ... rush delivery. , Each bottle contains cutting-edge, proven ... that don't work as well as we age. ...
Breaking Medicine News(10 mins):Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2
... 24 (HealthDay News) -- Obesity is costing states up to ... nine states, obesity already accounts for 10 percent or more ... RTI International, Duke University and the U.S. Agency for Healthcare ... are footing a large part of the bill, with the ...
... By Jenifer Goodwin HealthDay Reporter , WEDNESDAY, Aug. ... and watch "suggestive" TV shows are more likely to use drugs ... new survey found. The survey included more than 1,000 youths ... of their parents. On a typical day, about 70 percent of ...
... 24 (HealthDay News) -- High doses of the popular ... and should no longer be prescribed to patients, the ... of Celexa (citalopram hydrobromide) greater than 40 milligrams a ... the heart, which can lead to abnormal heart rhythms, ...
... August 2011 The fight against non-communicable diseases (NCDs) such ... disease, is at grave risk, because of recent efforts by ... the European Association for the Study of the Liver (EASL) ... Ban Ki-Moon, Dr Margaret Chan and Mr Jose Manuel Barroso, ...
... first evidence that older brains get more benefit than ... via trial-and-error learning. The study was led by ... and appears online Aug. 24, 2011 in the journal ... edition. The finding will surprise professional educators ...
... California as well as others in Canada and the ... into major motion pictures that depict smoking -- leading ... University of California, San Francisco (UCSF) researcher has found. ... Medicine , those subsidies, along with government inaction on ...
Cached Medicine News:Health News:Obesity Costing States Billion in Yearly Medical Expenses 2Health News:Teen Drinking, Smoking Higher Among Facebook Users: Survey 2Health News:Teen Drinking, Smoking Higher Among Facebook Users: Survey 3Health News:UN Member States jeopardize international progress on non-communicable disease epidemic 2Health News:Learning information the hard way may be best 'boot camp' for older brains 2Health News:Taxpayer film subsidies promote youth smoking 2
...
Lacrimal Cannula, Straight, Stepped DownSize: 19g x 1-1/2"....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Medicine Products: